TEMPO study added support for Azilect in PD patients

Links shared publicly online about this topic.

968
total visits

TEMPO study added support for Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

View full resource at news-medical.net

Tags: Parkinson's Disease, Disease and Condition, Pharma, Teva Pharmaceutical Industries, disease, Safety